The purpose of this core is to provide a centralized laboratory resource for cryopreservation and distribution of patient samples and to monitor the kinetics of immunologic reconstitution following allogeneic hematopoietic stem cell transplantation (HSCT). Prior to transplantation, peripheral blood mononuclear cells (PBMC), bone marrow and serum or plasma are obtained from all patients enrolled on clinical trials supported by this Program Project. PBMC and plasma or serum are also obtained from normal stem cell donors for these individuals. Following HSCT, PBMC, DNA and plasma samples are cryopreserved at regular intervals. These samples are made available to all of the investigators in this program. Immune reconstitution after HSCT is evaluated through a variety of methods that provide a quantitative assessment of specific lymphocyte populations as well as their level of maturation and function. Quantitative analysis of circulating lymphocytes is determined by multi-parameter flow cytometry with a panel of fluorochrome-conjugated monoclonal antibodies. This is primarily evaluated using fresh samples and semi-automated methods for immunofluorescence analysis of whole blood. Assays of immune function primarily utilize cryopreserved PBMC. Reconstitution of T cell receptor repertoire is examined by the method of TCR Vp spectratyping. Thymic function is evaluated by quantitative PCR measurement of T-cell receptor excision circles (TREC) in PBMC. Reconstitution of T cell immunity to specific target antigens such as CMV and EBV is determined by ELISPOT. Results of each of these assays can be correlated with other parameters of immune function as well as with clinical outcomes. The availability of pre-HSCT samples as well as normal donor samples provides additional control populations and will allow additional comparisons. This core has 3 Specific Aims: 1. To obtain, isolate and cryopreserve mononuclear cells, DNA, RNA, plasma and serum components from patient samples for subsequent study by program investigators. 2. To maintain a computerized inventory of banked samples, assure patient privacy and distribute samples in a timely and equitable fashion to laboratory investigators for experiments proposed in this application. 3. To provide phenotypic and functional measurements of immune reconstitution in peripheral blood, bone marrow and targeted skin biopsies following allogeneic HSCT.

Public Health Relevance

Allogeneic stem cell transplantation provides effective therapy for many patients with hematologic cancers. However, some patients develop toxicities related to engraftment of donor immune cells. This core will be responsible for obtaining blood samples from patients at defined times before and after transplantation and will use these samples to assess the status of immune reconstitution. Patient confidentiality will be maintained and samples will only be obtained from patients who have provided informed consent.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Program Projects (P01)
Project #
5P01CA142106-10
Application #
8468139
Study Section
Heart, Lung, and Blood Initial Review Group (HLBP)
Project Start
Project End
2015-03-31
Budget Start
2013-04-01
Budget End
2014-03-31
Support Year
10
Fiscal Year
2013
Total Cost
$285,702
Indirect Cost
$97,992
Name
Dana-Farber Cancer Institute
Department
Type
DUNS #
076580745
City
Boston
State
MA
Country
United States
Zip Code
02215
Cutler, Corey S; Koreth, John; Ritz, Jerome (2017) Mechanistic approaches for the prevention and treatment of chronic GVHD. Blood 129:22-29
Ho, Vincent T; Kim, Haesook T; Bavli, Natalie et al. (2017) Vaccination with autologous myeloblasts admixed with GM-K562 cells in patients with advanced MDS or AML after allogeneic HSCT. Blood Adv 1:2269-2279
Gartlan, Kate H; Bommiasamy, Hemamalini; Paz, Katelyn et al. (2017) A critical role for donor-derived IL-22 in cutaneous chronic GVHD. Am J Transplant :
MacDonald, Kelli Pa; Blazar, Bruce R; Hill, Geoffrey R (2017) Cytokine mediators of chronic graft-versus-host disease. J Clin Invest 127:2452-2463
MacDonald, Kelli P A; Hill, Geoffrey R; Blazar, Bruce R (2017) Chronic graft-versus-host disease: biological insights from preclinical and clinical studies. Blood 129:13-21
Wang, Kathy S; Kim, Haesook T; Nikiforow, Sarah et al. (2017) Antibodies targeting surface membrane antigens in patients with chronic graft-versus-host disease. Blood 130:2889-2899
Asano, Takeru; Meguri, Yusuke; Yoshioka, Takanori et al. (2017) PD-1 modulates regulatory T-cell homeostasis during low-dose interleukin-2 therapy. Blood 129:2186-2197
Du, Jing; Paz, Katelyn; Flynn, Ryan et al. (2017) Pirfenidone ameliorates murine chronic GVHD through inhibition of macrophage infiltration and TGF-? production. Blood 129:2570-2580
McKenna Jr, David H; Sumstad, Darin; Kadidlo, Diane M et al. (2017) Optimization of cGMP purification and expansion of umbilical cord blood-derived T-regulatory cells in support of first-in-human clinical trials. Cytotherapy 19:250-262
Du, Jing; Paz, Katelyn; Thangavelu, Govindarajan et al. (2017) Invariant natural killer T cells ameliorate murine chronic GVHD by expanding donor regulatory T cells. Blood 129:3121-3125

Showing the most recent 10 out of 186 publications